Cryolife Europa Ltd

General information

CryoLife’s mission is to restore patients’ health and quality of life by delivering innovative technologies.

CryoLife is one of the world’s leading contemporary medical device companies, providing preserved human tissues for cardiac and vascular surgeries, mechanical heart valves for aortic or mitral valve replacement, surgical adhesives and sealants, cardiac lasers for treatment of refractory angina, and state-of-the-art technology and surgical training in adult and pediatric cardiovascular surgery.

CryoLife is a pioneer and leader in processing, preserving and distributing human tissues, for use in cardiac and vascular surgeries. Founded in 1984, CryoLife was the first biomedical company to specialize in low temperature preservation of human heart valves used for complex cardiac reconstruction, primarily in children born with heart defects.

Since the company’s inception, it is estimated that Cryolife has received tissues from over 145,000 donors and CryoLife products and tissues have been implanted in over 1 million patients worldwide.

CryoLife is headquartered in Kennesaw, Georgia, with offices in Austin, Texas and Guildford, Surrey, UK, as well as sales and marketing centers in Germany and Singapore, and representation in over 85 countries worldwide.

The firm’s 650 employees hail from 11 countries and speak 17 languages. CryoLife’s staff includes four full-time physicians and seven Ph.D.s, with disciplines in chemical engineering, biomedical engineering, biochemistry, protein chemistry and organic chemistry.

CryoLife is a public company and is traded on the New York Stock Exchange under the symbol CRY.